Newron Pharma: Preclinical Study Shows Therapeutic Potential Of Evenamide
(RTTNews) - Newron Pharmaceuticals reported the publication of preclinical research in the peer-reviewed journal Neuropsychopharmacology on the mechanism and site of action of evenamide as a potential treatment for schizophrenia. The findings, using the neurodevelopmental methylazoxymethanol acetate animal model, indicated that evenamide, Newron's glutamate modulator, could offer a therapeutic strategy capable of addressing positive, cognitive, and negative symptoms of schizophrenia.
"The study findings suggest that evenamide has high therapeutic potential for treating multiple symptom domains of schizophrenia," said Senior study author Anthony Grace of the University of Pittsburgh.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.